Theriva Biologics to Reverse Split 1-for-30 December 1
The NYSE American-listed clinical-stage company will trade on a split-adjusted basis beginning December 2, 2026.
Updated on Nov. 20, 2026 in Business

Theriva Biologics, Inc. has approved a reverse stock split at a ratio of one new share for every thirty old shares, effective at 11:59 p.m. Eastern Time on December 1, 2026. Its common stock will continue to trade on the NYSE American under the ticker TOVX, under new CUSIP number 87164U607.
Why it matters
The Company says the reverse split is intended to help it meet the per-share price requirements of the NYSE American. For Maryland-based investors and shareholders, the change reduces the share count while leaving the Company's listing and ticker unchanged.
Outstanding common shares will drop from 45,892,668 to roughly 1,529,756, and authorized common shares from 350,000,000 to 11,666,666 under the 1-for-30 ratio. Stockholders holding fractional shares will receive an additional fractional share to round up to a whole share.
The players
Theriva Biologics, Inc.
A clinical-stage company developing therapeutics for cancer and related diseases, headquartered in Rockville, Maryland, and listed on the NYSE American under the ticker TOVX.
Equiniti Trust Company
A transfer agent and shareholder services provider that is also acting as exchange agent for Theriva Biologics' reverse stock split.
The details
The Board of Directors authorized the split on November 13, 2026, and the Company will file a certificate of change with the Nevada Secretary of State to effect it. Equiniti Trust Company, the Company's transfer agent, is also acting as exchange agent, and proportionate adjustments will be made to outstanding warrants, stock options and equity incentive plan reserves.
Timeline
November 13, 2026: Board of Directors authorizes the reverse stock split.
December 1, 2026, 11:59 p.m. ET: Reverse stock split becomes effective.
December 2, 2026: Split-adjusted trading begins when the market opens.
Listing Standards
The reverse split is being effected to help Theriva Biologics meet the per-share price requirements of the NYSE American, a common reason small-cap issuers pursue this step. By keeping its listing and ticker, the Company is attempting to maintain its exchange status rather than face delisting.
Shareholders will hold roughly one new share for every thirty old shares, with fractional holdings rounded up to a whole share. Investors should check their brokerage accounts after December 2 for the split-adjusted position and the new CUSIP 87164U607.
The takeaway
Investors holding Theriva Biologics shares should expect a smaller share count with the same ticker, and should confirm their split-adjusted holdings with their broker once trading resumes on December 2, 2026.
What happens next
The reverse stock split takes effect at 11:59 p.m. ET on December 1, 2026, and split-adjusted trading begins on December 2, 2026.
Further reading
For more on other corporate actions by listed firms, browse Public Companies coverage across Maryland.
Source note: This article includes information reported by The Manila times.






